Showing results (101-110 of 207) with videos related to

Sort By:
Pageof 21
Haematologica|August 26, 2003
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomasPeter Borchmann, Franck Morschhauser, Anne Parry, et al.
The New England Journal of Medicine|June 13, 2003
Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's diseaseVolker Diehl, Jeremy Franklin, Michael Pfreundschuh, et al.
Cancer Immunity|June 28, 2003
Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patientsAxel Mischo, Andreas Wadle, Kristin Wätzig, et al.
Blood|May 19, 2011
Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MMSandra Grass, Klaus-Dieter Preuss, Stephan Thome, et al.
Blood|December 4, 2013
Suboptimal dosing of rituximab in male and female patients with DLBCLMichael Pfreundschuh, Carsten Müller, Samira Zeynalova, et al.
Digestive Diseases and Sciences|March 5, 2014
Proinflammatory progranulin antibodies in inflammatory bowel diseasesLorenz Thurner, Elisabeth Stöger, Natalie Fadle, et al.
Blood|March 16, 2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHLMichael Pfreundschuh, Lorenz Trümper, Marita Kloess, et al.
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
Blood|January 13, 2016
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphomaAndreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, et al.
British Journal of Haematology|December 7, 2018
Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trialBirte Friedrichs, Maike Nickelsen, Marita Ziepert, et al.
Pageof 21